NASDAQ:FREQ - Frequency Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $37.00
  • Forecasted Upside: 264.53 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$10.15
▲ +0.39 (4.00%)
1 month | 3 months | 12 months
Get New Frequency Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for FREQ and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for FREQ

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$37.00
▲ +264.53% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Frequency Therapeutics in the last 3 months. The average price target is $37.00, with a high forecast of $56.00 and a low forecast of $20.00. The average price target represents a 264.53% upside from the last price of $10.15.
Buy
The current consensus among 3 investment analysts is to buy stock in Frequency Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/30/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/28/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/27/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/26/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/24/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/22/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/23/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/22/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/30/2021OppenheimerLower Price TargetOutperform$68.00 ➝ $20.00Medium
i
3/24/2021B. RileyLower Price TargetBuy$79.00 ➝ $35.00High
i
Rating by M. Mamtani at B. Riley
3/24/2021OppenheimerLower Price TargetOutperform$68.00 ➝ $20.00Medium
i
2/11/2021OppenheimerBoost Price TargetOutperform$48.00 ➝ $68.00Low
i
1/27/2021JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$56.00High
i
12/22/2020B. RileyInitiated CoverageBuyLow
i
Rating by M. Mamtani at B. Riley
12/16/2020OppenheimerBoost Price TargetOutperform$36.00 ➝ $48.00High
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
7/13/2020OppenheimerInitiated CoverageOutperform$36.00High
i
5/18/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$28.00 ➝ $27.00High
i
3/27/2020JPMorgan Chase & Co.Boost Price TargetOverweight$26.00 ➝ $28.00High
i
11/18/2019CowenReiterated RatingBuyMedium
i
10/28/2019The Goldman Sachs GroupInitiated CoverageBuy$30.00High
i
10/28/2019JPMorgan Chase & Co.Initiated CoverageOverweight$25.00High
i
10/28/2019CowenInitiated CoverageOutperformHigh
i
(Data available from 4/22/2016 forward)
Frequency Therapeutics logo
Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on harnessing the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. Its Progenitor Cell Activation approach, uses combinations of small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in phase 2a clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. Frequency Therapeutics, Inc. has a licencse and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322. Frequency Therapeutics, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.
Read More

Today's Range

Now: $10.15
$9.75
$10.29

50 Day Range

MA: $21.85
$7.99
$47.20

52 Week Range

Now: $10.15
$7.34
$58.37

Volume

2,306 shs

Average Volume

1,218,053 shs

Market Capitalization

$346.91 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.69

Frequently Asked Questions

What sell-side analysts currently cover shares of Frequency Therapeutics?

The following Wall Street research analysts have issued stock ratings on Frequency Therapeutics in the last twelve months: B. Riley, JPMorgan Chase & Co., Oppenheimer Holdings Inc., TheStreet, and Zacks Investment Research.
View the latest analyst ratings for FREQ.

What is the current price target for Frequency Therapeutics?

3 Wall Street analysts have set twelve-month price targets for Frequency Therapeutics in the last year. Their average twelve-month price target is $37.00, suggesting a possible upside of 279.9%. JPMorgan Chase & Co. has the highest price target set, predicting FREQ will reach $56.00 in the next twelve months. Oppenheimer Holdings Inc. has the lowest price target set, forecasting a price of $20.00 for Frequency Therapeutics in the next year.
View the latest price targets for FREQ.

What is the current consensus analyst rating for Frequency Therapeutics?

Frequency Therapeutics currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe FREQ will outperform the market and that investors should add to their positions of Frequency Therapeutics.
View the latest ratings for FREQ.

What other companies compete with Frequency Therapeutics?

How do I contact Frequency Therapeutics' investor relations team?

Frequency Therapeutics' physical mailing address is 19 PRESIDENTIAL WAY SUITE 203, WOBURN MA, 01801. The company's listed phone number is 866-389-1970 and its investor relations email address is [email protected] The official website for Frequency Therapeutics is www.frequencytx.com.